James Kempson

List of Publications by Year
in descending order

32	672	858243 12	651938 25
papers	citations	h-index	g-index

33	33	33	901
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Advances in the synthesis of three-dimensional molecular architectures by dearomatizing photocycloadditions. Tetrahedron, 2022, 103, 132087.	1.0	12
2	Synthesis Optimization, Scale-Up, and Catalyst Screening Efforts toward the MGAT2 Clinical Candidate, BMS-963272. Organic Process Research and Development, 2022, 26, 1327-1335.	1.3	4
3	A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist. Journal of Organic Chemistry, 2021, 86, 8851-8861.	1.7	7
4	Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1143-1150.	1.3	3
5	Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide. Organic Process Research and Development, 2021, 25, 1680-1689.	1.3	3
6	Large-scale supercritical fluid chromatography purification of unstable STING agonist intermediates. Journal of Chromatography A, 2021, 1651, 462309.	1.8	5
7	Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity. Journal of Organic Chemistry, 2021, 86, 1730-1747.	1.7	45
8	Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. Journal of Medicinal Chemistry, 2021, 64, 14773-14792.	2.9	7
9	Long-Acting Tumor-Activated Prodrug of a TGFÎ²R Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 15787-15798.	2.9	2
10	Intramolecular [2+2] Cycloaddition of Nâ€Allylcinnamamines and Nâ€Allylcinnamamides by Visibleâ€Light Photocatalysis. European Journal of Organic Chemistry, 2020, 2020, 41-46.	1.2	16
11	Synthesis of 1-(tert-Butyl) 4-Methyl (1R,2S,4R)-2-Methylcyclohexane-1,4-dicarboxylate from Hagemannâ€™s tert-Butyl Ester for an Improved Synthesis of BMS-986251. Journal of Organic Chemistry, 2020, 85, 10988-10993.	1.7	7
12	Route evaluation and development of a practical synthesis of methyl (S)-2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-7-carboxylate. Tetrahedron, 2020, 76, 131624.	1.0	1
13	Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. ACS Medicinal Chemistry Letters, 2020, 11, 2195-2203.	1.3	6
14	Synthesis of Cyclobutane-Fused Tetracyclic Scaffolds via Visible-Light Photocatalysis for Building Molecular Complexity. Journal of the American Chemical Society, 2020, 142, 3094-3103.	6.6	92
15	Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry, 2019, 62, 8973-8995.	2.9	212
16	Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. ACS Medicinal Chemistry Letters, 2019, 10, 306-311.	1.3	11
17	BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder. ACS Medicinal Chemistry Letters, 2018, 9, 472-477.	1.3	13
18	Evolution of a Scale-Up Synthesis to a Potent GluN2B Inhibitor and Its Prodrug. Organic Process Research and Development, 2018, 22, 846-855.	1.3	5

#	Article	IF	Citations
19	Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3101-3106.	1.0	10
20	Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 377-393.	1.3	15
21	Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4908-4913.	1.0	12
22	Discovery of highly potent, selective, covalent inhibitors of JAK3. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4622-4625.	1.0	24
23	Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 845-849.	1.3	11
24	Novel tricyclic inhibitors of IKK2: Discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7006-7012.	1.0	12
25	Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 383-386.	1.0	11
26	Periodic, Partial Inhibition of IÎºB Kinase Î²-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 349-360.	1.3	26
27	Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1935-1938.	1.0	20
28	Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IÎºB kinase. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2646-2649.	1.0	19
29	Novel Tricyclic Inhibitors of IÎºB Kinase. Journal of Medicinal Chemistry, 2009, 52, 1994-2005.	2.9	25
30	Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structureâ€“activity relationships. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1829-1833.	1.0	35
31	Fused Pyrimidine Based Inhibitors of Phosphodiesterase 7 (PDE7): Synthesis and Initial Structureâ€”Activity Relationships.. ChemInform, 2005, 36, no.	0.1	0
32	Development of a Rapid Scale-Up Synthesis of (S)-N-(8-((2-Amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide, a Potent Adaptor-Associated Kinase 1 Inhibitor. Organic Process Research and Development, 0, , .	1.3	4